SRRA - シエラ・オンコロジ― （Sierra Oncology Inc.）

GlaxoSmithKline (GSK) has completed its acquisition of Sierra Oncology after the latter''s shareholders approved the deal on June 29.

GSK announced it has completed the acquisition of Sierra Oncology, a California-based biopharmaceutical company.

Astrazeneca PLC found using ticker (AZN) have now 5 analysts in total covering the stock. The consensus rating is ''Buy''. The range between the high target price and low target price is between 80 and 59 with a mean TP of 71.8. Given that the stocks previous close was at 64.45 this indicates there is a potential upside of 11.4%. The 50 day MA is 65.02 and the 200 day MA is 61.05. The market cap for the company is $207,319m. You can visit the company''s website by visiting: https://www.astrazeneca.com [stock_market_widget type="chart" template="basic" color="green" assets="AZN" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $230,962m based on the market concensus. AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.

Sierra Oncology Inc (SRRA) shares closed today at 0.5% below its 52 week high of $55.17, giving the company a market cap of $1B. The stock is currently up 152.5% year-to-date, up 199.3% over the past 12 months, and up 20.4% over the past five years. This week, the Dow Jones Industrial Average fell 4.8%, and the S&P 500 fell 5.7%. Trading Activity Trading volume this week was 16.3% lower than the 20-day average.Beta, a measure of the stock’s volatility relative to the overall market stands at 0.5. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold.The stock closed at 0.0% lower than its 5-day moving average, 0.1% higher than its 20-day moving average, and 24.3% higher than its 90-day moving average. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , beats it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -1320.8% The company's stock price performance over the past 12 months beats the peer average by -1254.0% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.

GlaxoSmithKline (GSK) has completed its acquisition of Sierra Oncology after the latter''s shareholders approved the deal on June 29.

GSK announced it has completed the acquisition of Sierra Oncology, a California-based biopharmaceutical company.

Astrazeneca PLC found using ticker (AZN) have now 5 analysts in total covering the stock. The consensus rating is ''Buy''. The range between the high target price and low target price is between 80 and 59 with a mean TP of 71.8. Given that the stocks previous close was at 64.45 this indicates there is a potential upside of 11.4%. The 50 day MA is 65.02 and the 200 day MA is 61.05. The market cap for the company is $207,319m. You can visit the company''s website by visiting: https://www.astrazeneca.com [stock_market_widget type="chart" template="basic" color="green" assets="AZN" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $230,962m based on the market concensus. AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.

Sierra Oncology Inc (SRRA) shares closed today at 0.5% below its 52 week high of $55.17, giving the company a market cap of $1B. The stock is currently up 152.5% year-to-date, up 199.3% over the past 12 months, and up 20.4% over the past five years. This week, the Dow Jones Industrial Average fell 4.8%, and the S&P 500 fell 5.7%. Trading Activity Trading volume this week was 16.3% lower than the 20-day average.Beta, a measure of the stock’s volatility relative to the overall market stands at 0.5. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold.The stock closed at 0.0% lower than its 5-day moving average, 0.1% higher than its 20-day moving average, and 24.3% higher than its 90-day moving average. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , beats it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -1320.8% The company's stock price performance over the past 12 months beats the peer average by -1254.0% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.

Astrazeneca PLC with ticker code (AZN) now have 5 analysts covering the stock with the consensus suggesting a rating of ''Buy''. The target price ranges between 70 and 59.5 and has a mean target at 66.98. With the stocks previous close at 66.34 this would indicate that there is a potential upside of 1.0%. There is a 50 day moving average of 60.54 while the 200 day moving average is 59.03. The market cap for the company is $207,036m. You can visit the company''s website by visiting: https://www.astrazeneca.com [stock_market_widget type="chart" template="basic" color="green" assets="AZN" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $209,034m based on the market concensus. AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.

Astrazeneca PLC with ticker code (AZN) have now 5 analysts in total covering the stock. The consensus rating is ''Buy''. The range between the high target price and low target price is between 70 and 59.5 with a mean TP of 66.98. Given that the stocks previous close was at 66.02 this indicates there is a potential upside of 1.5%. The 50 day moving average now sits at 59.84 and the 200 day MA is 58.83. The company has a market cap of $201,830m. Find out more information at: https://www.astrazeneca.com [stock_market_widget type="chart" template="basic" color="green" assets="AZN" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $204,765m based on the market concensus. AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.

Astrazeneca PLC found using ticker (AZN) now have 5 analysts covering the stock. The analyst consensus points to a rating of ''Buy''. The target price ranges between 70 and 59.5 with a mean TP of 66.98. Now with the previous closing price of 63.23 this is indicating there is a potential upside of 5.9%. The 50 day moving average now sits at 59.15 and the 200 day MA is 58.65. The company has a market cap of $196,144m. Find out more information at: https://www.astrazeneca.com [stock_market_widget type="chart" template="basic" color="green" assets="AZN" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $207,776m based on the market concensus. AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products lude Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.

Astrazeneca PLC found using ticker (AZN) have now 5 analysts covering the stock with the consensus suggesting a rating of ''Buy''. The range between the high target price and low target price is between 70 and 59.5 calculating the average target price we see 66.98. Given that the stocks previous close was at 60.9 this now indicates there is a potential upside of 10.0%. The day 50 moving average is 58.73 and the 200 moving average now moves to 58.51. The market cap for the company is $188,315m. Find out more information at: https://www.astrazeneca.com [stock_market_widget type="chart" template="basic" color="green" assets=AZN" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $207,116m based on the market concensus. AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.

Sierra Oncology press release (SRRA): Q4 Non-GAAP EPS of -$1.44. Cash and cash equivalents totaled $104.7 million as of December 31, 2021, compared to $104.1 million as of December…